| 136.35 -3.65 (-2.61%) | 09-17 15:39 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 181.58  |
1-year : | 194.74 |
| Resists | First : | 155.46 |
Second : | 166.72 |
| Pivot price | 144.38 |
|||
| Supports | First : | 137.25 |
Second : | 114.19 |
| MAs | MA(5) : | 140.58 |
MA(20) : | 145.52 |
| MA(100) : | 146.9 |
MA(250) : | 161.87 |
|
| MACD | MACD : | -2.6 |
Signal : | -1.4 |
| %K %D | K(14,3) : | 6.7 |
D(3) : | 12.9 |
| RSI | RSI(14): 38.4 |
|||
| 52-week | High : | 211.13 | Low : | 110.44 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ RGEN ] has closed above bottom band by 3.5%. Bollinger Bands are 46.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 7 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 142.07 - 142.92 | 142.92 - 143.75 |
| Low: | 137.86 - 138.88 | 138.88 - 139.85 |
| Close: | 138.46 - 139.94 | 139.94 - 141.36 |
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and SpectraFlo dynamic dialysis systems; and ProConnex single-use hollow fiber. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. Repligen Corporation was incorporated in 1981 and is headquartered in Waltham, Massachusetts.
Fri, 13 Sep 2024
Daiwa Securities Group Inc. Buys 14,166 Shares of Repligen Co. (NASDAQ:RGEN) - MarketBeat
Thu, 12 Sep 2024
Repligen Co. (NASDAQ:RGEN) Director Anthony Hunt Sells 22,191 Shares - MarketBeat
Thu, 12 Sep 2024
Repligen director Hunt Anthony sells over $3.2 million in company stock - Investing.com
Wed, 11 Sep 2024
Several Headwinds Dragged Repligen Corporation (RGEN) in Q2 - Insider Monkey
Sat, 07 Sep 2024
Repligen Corporation (RGEN) Fell Due to CEO Transition - Yahoo Finance
Fri, 23 Aug 2024
Repligen Corporation (RGEN) Benefitted From Drug Approval - Insider Monkey
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Instruments & Supplies
|
|
| Shares Out | 56 (M) |
| Shares Float | 52 (M) |
| Held by Insiders | 6.5 (%) |
| Held by Institutions | 104.9 (%) |
| Shares Short | 4,050 (K) |
| Shares Short P.Month | 4,390 (K) |
| EPS | -0.03 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 35.52 |
| Profit Margin | -0.4 % |
| Operating Margin | 1.6 % |
| Return on Assets (ttm) | 0.1 % |
| Return on Equity (ttm) | -0.2 % |
| Qtrly Rev. Growth | -3.3 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 10.75 |
| EBITDA (p.s.) | 1.4 |
| Qtrly Earnings Growth | -83 % |
| Operating Cash Flow | 155 (M) |
| Levered Free Cash Flow | 120 (M) |
| PE Ratio | -4587.67 |
| PEG Ratio | 6.6 |
| Price to Book value | 3.87 |
| Price to Sales | 12.79 |
| Price to Cash Flow | 49.67 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|